Of note, in both cases, TP53 mutant clones accounted for <1% of the total hematopoietic output, supporting the notion that the nature of mutations and biological context, rather than clone size, determine the oncologic potential of CH. This evidence concerns the gene TP53 and cyclic hematopoiesis.